Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Feature|Videos|June 25, 2026
Building Long-Term Value Through Functional Service Provider Partnerships
Author(s)Diana Cucos, President FSP 360, Syneos Health
Key Takeaways
- Understand how Syneos Health's FSP model differs from short-term staffing augmentation.
- Follow the logic of building a global talent hub to support continuity in clinical trials.
Diana Cucos, President FSP 360 at Syneos Health, describes their functional service provider (FSP) model and AbbVie partnership, highlighting how execution builds long-term clinical trial value.
The clinical trial industry has a range of staffing approaches, from small providers that offer short-term team augmentation to FSP models built around long-term value creation. Sponsors evaluating these options must weigh not only immediate staffing needs but also how a partner will support process improvement, innovation, and value creation over time. Diana Cucos, President FSP 360 at Syneos Health, describes their FSP approach as one that goes beyond placing a team. They become embedded within a sponsor's operations and work to understand evolving needs. Working with AbbVie, she discusses how the companies selected Spain as a talent destination before expanding to a hub in Latin America, building a global team intended to support continuity in clinical trials. Industry innovation depends on execution, which requires a partner able to integrate new ideas into a sponsor's existing operating model.
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5